Qualigen Therapeutics Surges to 378th Most Traded Stock with $28.1 Million Turnover Amidst Patent Milestone

On July 16, 2025, Qualigen Therapeutics (QLGN) experienced a significant surge in trading volume, with a turnover of $28.1 million, marking a 2044.41% increase from the previous day. This substantial rise in trading activity positioned Qualigen as the 378th most traded stock of the day. The company's stock price increased by 11.33%.

Qualigen Therapeutics has recently secured new patents for its cancer drug QN-302, covering 25 countries including most of Europe, India, and China. These patents, titled "Substituted Naphthalene Diimides and Their Use," protect both the product and its manufacturing methods. The patents extend until 2040, significantly strengthening Qualigen's position in the drug development sector, particularly for treating pancreatic and gastrointestinal cancers. The patents were developed by Professor Stephen Neidle's team at University College London.

This patent milestone has been a major driver for Qualigen's stock performance, with the company announcing significant progress in expanding the global patent coverage of its lead cancer drug candidate, QN-302. The patents encompass both the formulation of the product and the methods for its production, reinforcing Qualigen's strategy in drug development. The company's shares have seen a notable increase following the announcement of these patent approvals, reflecting investor confidence in the company's intellectual property and future prospects.